BCAX logo

BCAX
Bicara Therapeutics

84
Mkt Cap
$1.47B
Volume
6,262.00
52W High
$24.25
52W Low
$7.80
PE Ratio
-8.91
BCAX Fundamentals
Price
$22.72
Prev Close
$22.48
Open
$22.87
50D MA
$19.52
Beta
1.73
Avg. Volume
610,609.08
EPS (Annual)
-$2.52
P/B
3.17
Rev/Employee
$0.00
$507.12
Loading...
Loading...
News
all
press releases
Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an...
MarketBeat·6d ago
News Placeholder
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 15,000 Shares of Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction on Monday, April 20th. The stock was sold at an average price...
MarketBeat·7d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average...
MarketBeat·8d ago
News Placeholder
Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average...
MarketBeat·10d ago
News Placeholder
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer...
MarketBeat·11d ago
News Placeholder
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve brokerages that are currently covering the stock, Marketbeat reports...
MarketBeat·13d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week High - Time to Buy?
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month High - What's Next...
MarketBeat·15d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High - Here's Why
Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week High - Time to Buy...
MarketBeat·21d ago
News Placeholder
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings
Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for Bicara Therapeutics in a research report issued on Tuesday...
MarketBeat·26d ago
<
1
2
...
>

Latest BCAX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.